Phanes Therapeutics announces FDA IND clearance for PT199, a next generation monoclonal antibody against human CD73

SAN DIEGO, March 22, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology announced today that it has received clearance from the US Food and Drug Administration to commence Phase I studies…

Click here to view original post